AskMed

Drug Atorvastatin: Side Effects, Interactions and Safety

The drug atorvastatin has a well-mapped safety profile: serious harm is rare, while mild complaints are common and often not caused by the statin itself. A 2019 American Heart Association statement puts serious statin muscle injury, including rhabdomyolysis, below 0.1% of patients and serious liver injury at about 0.001%, with new diabetes diagnoses up by about 0.2% per year of treatment. The practical questions are muscle aches, interactions through the CYP3A4 enzyme, grapefruit juice, pregnancy and which blood tests are worth doing. This guide covers how common each adverse effect is, which medicines interact, who should not take atorvastatin under the US and UK labels, and what monitoring is recommended.

Statin safety questions rarely end with one source: the US label, the UK product information, MHRA updates and the trial meta-analyses each add a piece. AskMed is a medical question app made for doctors, nurses, pharmacists, medical students and researchers. It searches journals, clinical guidelines and drug labels first, then writes an answer with a link after every claim. A resident preparing to counsel on statins can ask AskMed what blinded trials show about muscle symptoms and how the MHRA has since changed statin product information, then check both against the paper.

Ask AskMed what blinded trials show about statin muscle symptoms:

How safe is the drug atorvastatin overall?

The drug atorvastatin, like the statin class it belongs to, has rare serious adverse effects when they are set against the cardiovascular events it prevents. The American Heart Association scientific statement led by Newman (2019) estimated what happens when 10,000 patients take a statin for five years and lower LDL cholesterol by 2 mmol/L. About 1,000 major vascular events are prevented in secondary prevention and about 500 in primary prevention. Against that, there are about 100 new diagnoses of diabetes, about 10 haemorrhagic strokes in people with prior cerebrovascular disease, about 5 cases of myopathy and about 1 case of rhabdomyolysis, and fewer than 1 case of severe liver disease. The statement found no convincing evidence that statins cause cancer, cataracts, cognitive dysfunction, peripheral neuropathy, erectile dysfunction or tendonitis, and concluded that in patients for whom guidelines recommend a statin, the benefits greatly outweigh the risks.

1,000major vascular events prevented (secondary prevention)
500major vascular events prevented (primary prevention)
100new diagnoses of diabetes
10haemorrhagic strokes (prior cerebrovascular disease)
5cases of myopathy
1case of rhabdomyolysis
Estimated benefits and harms per 10,000 patients on a statin for five years, lowering LDL cholesterol by 2 mmol/L (Newman 2019, Table 7). Severe liver disease: fewer than 1.

The US label adds the day-to-day picture of the adverse effects of atorvastatin. In the US Lipitor label's placebo-controlled database of 16,066 patients, 8,755 of them on atorvastatin, the most common adverse reactions that occurred in at least 2% of patients and more often than with placebo were nasopharyngitis (8.3%), arthralgia (6.9%), diarrhoea (6.8%), pain in an extremity (6.0%) and urinary tract infection (5.7%). The reactions that most often led to stopping treatment were myalgia (0.7%), diarrhoea (0.5%), nausea (0.4%) and raised liver enzymes. The NHS lists headache, dizziness, nausea, digestive problems, muscle aches, swollen joints, a blocked or runny nose, nosebleeds and sleep problems as common side effects.

How common are muscle symptoms with atorvastatin?

Muscle symptoms are the commonest reason people stop atorvastatin, yet blinded trials show the statin itself causes only a small share of them. The Cholesterol Treatment Trialists' (CTT) Collaboration pooled individual data from 19 double-blind trials of a statin against placebo, with 123,940 participants (Lancet, 2022). Muscle pain or weakness was reported by 27.1% of participants allocated a statin and 26.6% of those allocated placebo, a rate ratio of 1.03. The excess was concentrated in the first year, when the statin raised reports by 7%, an absolute excess of 11 events per 1,000 person-years; after the first year there was no significant excess. The authors concluded that more than 90% of muscle symptom reports from participants on a statin were not caused by the statin. Clinical practice looks different: the AHA statement notes that roughly 10% of patients in US practice stop a statin because of subjective complaints, most often muscle symptoms without a raised creatine kinase (CK).

Muscle pain or weakness reported Statin 27.1% Placebo 26.6% 19 double-blind trials, 123,940 participants
Almost as many people on placebo reported muscle symptoms as people on a statin (CTT Collaboration, Lancet 2022).

Regulators have acted on this evidence. In its January 2026 Safety Roundup, the MHRA said it had reviewed the nocebo effect after the CTT analysis and is updating product information across the statin class to state that statins caused a small relative increase (3%) in first reports of mild muscle pain or weakness, largely confined to the first year, and that more than 90% of muscle symptom reports on statins were not caused by the statin. Two rarer muscle problems are real, though. The US label describes immune-mediated necrotising myopathy, an autoimmune myopathy with proximal weakness and a raised CK that persists after the statin is stopped and a positive anti-HMG-CoA reductase antibody, and says to stop atorvastatin if it is suspected. And in September 2023 the MHRA reported very infrequent cases of new or worsening myasthenia gravis with statins (10 UK Yellow Card reports from 1995 to June 2023), mostly resolving after the statin was stopped.

When can atorvastatin cause rhabdomyolysis?

Rhabdomyolysis, a breakdown of skeletal muscle that can lead to acute kidney injury, is the most serious muscle adverse effect of atorvastatin, and it is rare. The AHA statement puts the risk of statin-induced serious muscle injury, including rhabdomyolysis, below 0.1%, and its benefit-risk table estimates about 1 case of rhabdomyolysis per 10,000 patients over five years. Myopathy, defined there as unexplained muscle pain or weakness with CK above 10 times the upper limit of normal, occurs in about 5 per 10,000. The US label names the risk factors: age 65 or older, uncontrolled hypothyroidism, renal impairment, use with certain other drugs including other lipid-lowering therapies, and higher-intensity treatment. The label tells prescribers to stop atorvastatin if CK becomes markedly raised or if myopathy is diagnosed or suspected, and to pause it temporarily during an acute or serious condition that carries a high risk of kidney failure from rhabdomyolysis, such as sepsis, shock, severe hypovolaemia, major surgery or trauma.

The label asks that patients report unexplained muscle pain, tenderness or weakness promptly, particularly with malaise or fever, and notes that muscle symptoms and CK rises may resolve when atorvastatin is stopped. The NHS describes the warning signs of muscle damage as cramps, severe pain and weakness, sometimes with a high temperature and red or brown urine. Anyone with those symptoms on a statin should get medical advice promptly.

Does atorvastatin affect the liver?

Atorvastatin can raise liver enzymes, but true liver injury from the drug is very rare. In the US label, persistent increases in serum transaminases to more than three times the upper limit of normal occurred in about 0.7% of patients in clinical trials. The AHA statement puts confirmed transaminase rises above three times the upper limit at about 1% for statins overall and notes that the rise does not by itself indicate liver injury. Clinically apparent hepatotoxicity is far rarer, at about 0.001% of patients, and the statement says it is not currently possible to predict who will develop it. For that reason, the FDA's February 2012 safety communication removed routine periodic liver enzyme monitoring from statin labels, and the current atorvastatin label advises considering liver enzyme tests before starting and when clinically indicated thereafter. When a statin does raise transaminases, ALT nearly always rises more than AST; a larger AST rise points to another cause, such as muscle injury or alcohol.

Liver disease itself sets limits. The US label contraindicates atorvastatin in acute liver failure or decompensated cirrhosis and notes that blood levels of atorvastatin are markedly increased in chronic alcoholic liver disease. The UK product information is broader: it contraindicates atorvastatin in active liver disease or unexplained persistent transaminase rises above three times the upper limit of normal. At the other end, the AHA statement says limited data suggest statins are safe in fatty liver disease and with transaminase rises up to three times the upper limit. For working out the cause of a raised ALT on or off a statin, see our guide to elevated ALT levels.

Does atorvastatin raise blood sugar or diabetes risk?

Atorvastatin, like other statins, slightly raises blood glucose and the chance of a new diabetes diagnosis, mostly in people who are already close to the diagnostic threshold. The current US label warns that statins have been associated with increases in HbA1c and fasting serum glucose, a class warning the FDA added in its February 2012 safety communication. The AHA statement estimates the excess risk of newly diagnosed diabetes at about 0.2% per year of treatment, depending on the underlying diabetes risk of the population, and found that in people who already have diabetes the average HbA1c rise is small and usually of limited clinical significance. The MHRA reached the same view in 2012: the risk falls mainly on patients with raised fasting glucose, a history of hypertension, raised triglycerides or a raised body mass index, and the reduction in vascular risk outweighs the risk of diabetes, so it is not a reason to stop statin treatment.

The UK Lipitor product information defines patients at risk as those with a fasting glucose of 5.6 to 6.9 mmol/L, a body mass index above 30 kg/m², raised triglycerides or hypertension, and asks that they be monitored clinically and biochemically according to national guidelines. The AHA statement advises increasing efforts at diabetes prevention and screening patients at raised risk for diabetes, especially those on intensive statin therapy. The US label's advice is to optimise lifestyle measures, including regular exercise and a healthy body weight.

Which drugs and foods interact with atorvastatin?

Most serious atorvastatin interactions come from medicines that raise its blood level, because atorvastatin is a substrate of the liver enzyme CYP3A4 and of drug transporters, and higher levels raise the risk of myopathy and rhabdomyolysis. The US label says use with ciclosporin or gemfibrozil is not recommended, and the same applies to two antiviral combinations: tipranavir plus ritonavir, and glecaprevir plus pibrentasvir. For a wider group, the label asks prescribers to weigh risk against benefit and, for several of them, to keep atorvastatin at a lower intensity: azole antifungals and macrolide antibiotics, several HIV protease inhibitors and hepatitis C antivirals, and letermovir. Other lipid-lowering drugs add muscle risk of their own, so the label asks whether the benefit of fibrates or lipid-modifying niacin outweighs the extra risk, and it records cases of myopathy and rhabdomyolysis when colchicine is combined with atorvastatin. Grapefruit juice also inhibits CYP3A4, and the label advises avoiding large quantities of it.

On grapefruit, the AHA statement explains that the juice contains furanocoumarins that inhibit CYP3A4, and the NHS advises no more than 1 or 2 small glasses of grapefruit juice a day. Interaction questions are where a single list runs out, because the answer depends on the exact regimen and on whether the US and UK documents agree. A pharmacist or junior doctor reconciling medicines can ask AskMed whether atorvastatin should be paused during a course of clarithromycin, or how the label handles letermovir after a transplant, and get the relevant label sections quoted with links before the chart is signed.

Check an atorvastatin interaction against the label in AskMed:

Who should not take atorvastatin, and who needs caution?

Under the current US label, atorvastatin is contraindicated in only two situations: acute liver failure or decompensated cirrhosis, and hypersensitivity to atorvastatin or any of its excipients. Pregnancy is no longer on that list. On 20 July 2021 the FDA asked the makers of all statins to remove the contraindication against using these medicines in all pregnant patients. The FDA did not say statins are safe in pregnancy: health care professionals should discontinue statin therapy in most pregnant patients, or they can consider the ongoing therapeutic needs of the individual patient, particularly those at very high risk for cardiovascular events during pregnancy, such as patients with homozygous familial hypercholesterolaemia or a previous heart attack or stroke. The current atorvastatin label follows this wording: discontinue when pregnancy is recognised, or alternatively consider the ongoing therapeutic needs of the individual patient. The FDA kept its advice against breastfeeding on a statin and said unintended exposure in early pregnancy is unlikely to harm the baby.

The UK position is stricter. The Lipitor product information authorised in the UK still contraindicates atorvastatin in pregnancy, while breastfeeding and in women of childbearing potential who are not using appropriate contraception, as well as with glecaprevir/pibrentasvir and in active liver disease. The NHS says atorvastatin is not recommended in pregnancy, and that it may be possible to take it while breastfeeding after checking with a pharmacist or doctor. The NHS also lists groups for whom atorvastatin may not be suitable: people who have had an allergic reaction or other serious side effect from a statin, people with liver or kidney problems or an underactive thyroid, people with a personal or family history of a muscle condition such as myasthenia gravis, people who have had a bleed in the brain, and people who regularly drink a lot of alcohol.

The brain bleed caution comes from the SPARCL trial. In a post-hoc analysis described in the US label, among adults without coronary heart disease who had a stroke or transient ischaemic attack within the previous six months, haemorrhagic stroke occurred in 2.3% on atorvastatin and 1.4% on placebo, although fatal haemorrhagic stroke was similar in both groups; the label asks prescribers to weigh risk and benefit after a recent haemorrhagic stroke. When regulators disagree, as they do on pregnancy and breastfeeding, the exact wording matters. A cardiology or obstetrics trainee can ask AskMed how the 2021 FDA statin pregnancy change compares with the UK Lipitor product information for a patient with familial hypercholesterolaemia planning a pregnancy, and read each regulator's statement cited side by side.

Compare US and UK atorvastatin labelling in AskMed:

What monitoring do guidelines recommend on atorvastatin?

Safety monitoring on atorvastatin is targeted rather than routine. The current US label advises considering liver enzyme tests before starting atorvastatin and when clinically indicated thereafter, a policy the FDA adopted in 2012 because serious liver injury is rare and periodic testing had not been shown to prevent it. The AHA statement adds that CK should be measured in any patient with significant unexplained muscle symptoms, or with unexplained transaminase rises above three times the upper limit of normal, because both enzymes are found in muscle and liver. It also says hypothyroidism should always be ruled out, since it causes weakness and raised CK on its own, and that unusual or strenuous exercise is a common cause of muscle symptoms and high CK. For glucose, the UK product information and the MHRA advise clinical and biochemical monitoring of patients at risk of diabetes according to national guidelines, and the AHA statement advises screening those at raised risk.

  1. Before starting: liver enzymes; check age, thyroid and kidney function, and interacting medicines.
  2. Unexplained muscle symptoms: measure CK, rule out hypothyroidism, ask about strenuous exercise.
  3. Transaminases over 3 times the upper limit: measure CK to separate muscle from liver.
  4. At risk of diabetes: glucose or HbA1c monitoring as national guidelines set out.
Targeted safety checks on atorvastatin, from the US label, the UK product information and the AHA 2019 statement.

Stopping is often not the end of statin treatment. The AHA statement cites a large US cohort in which 10% of 107,835 patients stopped a statin because of an adverse event judged statin-related; of the 6,579 who were rechallenged, more than 90% could be restored to some form of statin treatment. Some symptoms need prompt care rather than a routine review. The NHS advises calling 111 if serious side effects are suspected, such as muscle pain with a high temperature or red or brown urine, or yellowing of the skin or the whites of the eyes, which can signal hepatitis. Swelling of the throat or tongue or difficulty breathing can be anaphylaxis and needs emergency care.

Frequently asked questions

What are the most common side effects of atorvastatin?

In the US label's placebo-controlled trials, the most common were nasopharyngitis (8.3%), joint pain (6.9%), diarrhoea (6.8%), pain in an arm or leg (6.0%) and urinary tract infection (5.7%). The NHS also lists headache, dizziness, nausea, muscle aches and sleep problems.

Is muscle pain on atorvastatin always caused by the drug?

No. In 19 blinded trials, 27.1% of people on a statin and 26.6% on placebo reported muscle pain or weakness, and the CTT Collaboration concluded that more than 90% of these reports were not caused by the statin. Severe pain, weakness or red or brown urine still needs urgent assessment.

Can you drink grapefruit juice with atorvastatin?

Small amounts are usually fine. The US label advises avoiding large quantities of grapefruit juice, because it inhibits the CYP3A4 enzyme that breaks atorvastatin down, and the NHS advises no more than 1 or 2 small glasses a day.

Is atorvastatin contraindicated in pregnancy?

Not in the US since 2021, when the FDA asked for the pregnancy contraindication to be removed from all statin labels. The FDA still advises stopping statins in most pregnant patients, and the UK product information still lists pregnancy and breastfeeding as contraindications.

Does atorvastatin cause memory loss?

The FDA added reports of memory loss and confusion to statin labels in 2012, describing them as generally not serious and reversible after stopping. The 2019 AHA statement found no convincing evidence that statins cause cognitive dysfunction.

Sources

  1. LIPITOR (atorvastatin calcium) tablets: US prescribing information. DailyMed, US National Library of Medicine. Revised 12/2022.
  2. US Food and Drug Administration. FDA requests removal of strongest warning against using cholesterol-lowering statins during pregnancy. Drug Safety Communication, 20 July 2021.
  3. US Food and Drug Administration. Important safety label changes to cholesterol-lowering statin drugs. Drug Safety Communication, 28 February 2012.
  4. Newman CB, Preiss D, Tobert JA, et al. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2019;39(2):e38-e81.
  5. Cholesterol Treatment Trialists' Collaboration. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. Lancet. 2022;400(10355):832-845.
  6. MHRA. MHRA Safety Roundup: January 2026 (statins: the nocebo effect in muscle-related events).
  7. MHRA. Statins: very infrequent reports of myasthenia gravis. Drug Safety Update, 26 September 2023.
  8. MHRA. Statins: risk of hyperglycaemia and diabetes. Drug Safety Update, January 2012.
  9. Lipitor film-coated tablets: Summary of Product Characteristics (UK). Electronic medicines compendium.
  10. NHS. Side effects of atorvastatin and Who can and cannot take atorvastatin. Reviewed 23 June 2026.

Cited medical answers
you can trust.

AskMed on iPhone, iPad, Android and the web.